Roivant CEO urges pa­tience on fu­ture af­ter $7B+ sale to Roche

Now that Roivant has end­ed months of ru­mors by sign­ing a deal to sell its an­ti-TL1A in­hibitor to Roche for $7.1 bil­lion up­front, every­one wants to know how the com­pa­ny plans to spend that mon­ey.

In an in­vestor call Mon­day morn­ing, an­a­lysts asked sev­er­al ques­tions about Roivant’s next steps. CEO Matt Gline stressed he and his team will “be pa­tient” when it comes to find­ing the right op­por­tu­ni­ty. He didn’t go in­to specifics about when the mon­ey will be spent (or on what) and said it’s too ear­ly to de­cide what to do with the cash.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER